Tesacof indications
Tesacof SYRUP indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).
Uses of Tesacof in details
Tesacof is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Tesacof description
Each tablet also contains lactose, maize or potato starch, gelatine and magnesium stearate as excipients.
The oral/inhalation solution also contains tartaric acid and methyl parahydroxybenzoate as excipients.
The syrup also contains tartaric acid, benzoic acid, sodium carboxymethylcellulose, glycerol, sorbitol solution, pharma flavor and ethanol as excipients.
Each capsule also contains lactose, cornstarch and magnesium stearate as excipients.
Tesacof is N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)amine hydrochloride.
Tesacof dosage
Unless otherwise prescribed, the following doses are recommended:
Tablet: Adults and Children >12 years: 8 mg (1 tab) thrice daily; 6-12 years: 4 mg (½ tab) thrice daily; 2-6 years: 4 mg (½ tab) twice daily.
Oral Solution:
Adults and Children >12 years: 4 mL thrice daily; 6-12 years: 2 mL thrice daily; 2-6 years: 20 drops thrice daily; <2 years: 10 drops thrice daily.Inhalation Solution (with aerosol apparatus): It is generally recommended to warm inhalation solution to body temperature before inhalation. Patients with bronchial asthma may be advised to commencing inhalation after they have taken their regular bronchospasmolytic therapy.
Adults: 4 mL. Children >12 years: 2 mL; 6-12 years: 1 mL; 2-6 years: 10 drops; <2 years: 5 drops. All doses to be taken twice daily.
The solution may be diluted 1:1 in physiological saline solution. In order to avoid precipitation, the solution should be inhaled immediately after mixing. The combined administration of inhalation and oral application intensifies the effect, and is especially suited for the commencement of treatment in cases where the full effect is to be reached quickly.
Syrup: Adults and Children >12 years: 5 ml (1 tsp) thrice daily.
At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
The syrup is sugar-free and therefore suitable for diabetics and small children.
Ampoule: Severe cases, before and after surgical intervention: 1 amp SC, IM or IV (duration of injection: 2-3 min) 2-3 times daily.
Capsule: Adults: 1 cap 3 times daily.
It is recommended for the initial phase of treatment usually lasting not more than a week.
Patients being treated with Tesacof should be notified of an expected increase in the flow of secretions.
Tesacof interactions
A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.
Tesacof SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.
The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.
Tesacof side effects
Tesacof’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to Tesacof.
Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.
Tesacof contraindications
Tesacof SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia.
Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Tesacof SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination.
Safety in pregnancy and lactation has not been established.
Active ingredient matches for Tesacof:
Bromhexine in Mexico.
Bromhexine hydrochloride in Mexico.
| Unit description / dosage (Manufacturer) | Price, USD |
| Solution; Oral; Bromhexine Hydrochloride 4 mg / 5 ml | |
| Solution; Oral; Bromhexine Hydrochloride 8 mg / 5 ml | |
List of Tesacof substitutes (brand and generic names): | |
| Terpect Tablet | |
| Terpect Tablet (Themis Medicare Ltd.) | $ 0.03 |
| THEOSAL PD | |
| THEOSAL PD SYRUP 1 bottle / 100 ML syrup each (Monichem Healthcare Pvt Ltd) | $ 0.63 |
| Thephidron (Indonesia) | |
| Thephidron 8 mg x 200's (Combiphar) | $ 2.88 |
| Tolmix (Venezuela) | |
| Topcure | |
| Topcure 170 ml Syrup (Serve Pharmaceuticals) | $ 0.02 |
| Topcure 100 ml Syrup (Serve Pharmaceuticals) | $ 0.02 |
| Topcure 60 ml Syrup (Serve Pharmaceuticals) | $ 0.02 |
| Torex BR | |
| Torex BR 100 ml Syrup (Torque Pharmaceuticals Pvt. Ltd.) | $ 0.03 |
| Torex BR 50 ml Syrup (Torque Pharmaceuticals Pvt. Ltd.) | $ 0.03 |
| Torex BR Syrup (Torque Pharmaceuticals Pvt. Ltd.) | $ 0.21 |
| Torex Tablet | |
| Torex Tablet (Torque Pharmaceuticals Pvt. Ltd.) | $ 0.04 |
| Toridran-N (Mexico) | |
| Torlin BR | |
| Torlin BR 60 ml Syrup (Laborate Pharmaceuticals India Ltd.) | $ 0.03 |
| Torlin BR 100 ml Syrup (Laborate Pharmaceuticals India Ltd.) | $ 0.03 |
| TORLIN BR 100MG/8MG/2.5MG SYRUP 1 bottle / 60 ML syrup each (Laborate Pharmaceuticals India Ltd.) | $ 0.14 |
| TORLIN BR 50MG/1.25MG/4MG SYRUP 1 bottle / 100 ML syrup each (Laborate Pharmaceuticals India Ltd.) | $ 0.20 |
| Torlin BR 100 mg/8 mg/2.5 mg Syrup (Laborate Pharmaceuticals India Ltd.) | $ 0.14 |
| Torlin BR 50 mg/1.25 mg/4 mg Syrup (Laborate Pharmaceuticals India Ltd.) | $ 0.20 |
| Torlin-BR (India) | |
| Torlin-BR Bromhexine hydrochloride 8 mg, Terbutaline sulphate 2.5 mg, Guaiphenesin 100 mg, Menthol0.5 mg. SYR / 100ml (Laborate) | $ 0.54 |
| Torlin-BR Bromhexine hydrochloride 8 mg, Terbutaline sulphate 2.5 mg, Guaiphenesin 100 mg, Menthol0.5 mg. SYR / 60ml (Laborate) | $ 0.35 |
| 100ml (Laborate) | $ 0.54 |
| 60ml (Laborate) | $ 0.35 |
| TORLIN-BR syr 100ml (Laborate) | $ 0.54 |
| TORLIN-BR syr 60ml (Laborate) | $ 0.35 |
| Tosantil (Paraguay) | |
| Tosantil 8mg/5ml (Paraguay) | |
| Toscalmin (Argentina) | |
| Toscof Expectorant | |
| Toscof Expectorant 100 ml Expectorant (Cipla Limited) | $ 0.02 |
| Tosisan (Colombia) | |
| Tosseque (Portugal) | |
| Tostop (Argentina) | |
| Tostop Forte (Argentina) | |
| Tostop Niños (Argentina, Paraguay) | |
| Toularynx Bromhexine (Belgium) | |
| Toularynx Bromhexine 5mg/5ml (Luxembourg) | |
| Traxine DX | |
| Traxine DX 100 ml Syrup (Technica Labs & Pharma Pvt Ltd) | $ 0.03 |
| Traxine-DX (India) | |
| Traxine-DX Dextromethorphan hydrobromide5 mg, Bromhexine hydrochloride4 mg, Chlorpheniramine maleate2 mg. SYR / 100ml (Technica Labs) | $ 0.54 |
| 100ml (Technica Labs) | $ 0.54 |
| TRAXINE-DX syr 100ml (Technica Labs) | $ 0.54 |
| Trekpleister Broomhexine HCl (Netherlands) | |
| Trekpleister Hoestdrank (Netherlands) | |
| Tricos Bron | |
| Tricos Bron 100 ml Syrup (Atlantic Pharmaceuticals) | $ 0.05 |
See 1947 substitutes for Tesacof | |
References
- PubChem. "bromhexine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Bromhexine". http://www.drugbank.ca/drugs/DB09019 (accessed September 17, 2018).
- MeSH. "Expectorants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Tesacof are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tesacof. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 1-5 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
